Kali-Extracts and Nouveau Announce Cannabis Extraction Partnership For Canadian Recreational Marijuana Market

Kali-Extracts and Nouveau Announce Cannabis Extraction Partnership For Canadian Recreational Marijuana Market

DALLAS, TX - December 21, 2018 -- InvestorsHub NewsWire -- Kali, Inc. (dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced plans with Nouveau Life Pharmaceuticals (USOTC: NOUV) to use KALY’s patented cannabis extraction process in Canada. NOUV has a cannabis cultivation business with operations in the U.S. and Canada. The two companies will work together to produce cannabis extracts utilizing KALY’s patented cannabis extraction process for the recreational marijuana market.

KALY currently produces pharmaceutical grade cannabis extracts that have been involved in multiple clinical trials in addition to utilizing its patented cannabis extraction process in the production of CBD infused nutrition and wellness products to include its own Hemp4mula and CBD infused waters produced by Puration, Inc. (USOTC: PURA) (“PURA”).

KALY is partners with PURA and NOUV in a joint venture named US Cannabis Health for the purpose of together developing partnerships with pharmaceutical companies to develop cannabis pharmaceuticals. US Cannabis Health recently announced its first agreement with Generex Biotechnology, Corp. (OTCQB: GNBT).

To learn more about the KALY and NOUV project announced today, follow developments online at www.kali-extracts.com.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

Kali, Inc.
Frederick Ferri
ir@kali-extracts.com
(214) 210-0459